• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

BioTuesdays: HDT Bio focused on global impact of mRNA vaccine platform

May 23, 2023 | In the News

Click here to view...

Empowered Patient Podcast: Advanced RNA Technology Cost-Effectively Creating mRNA Vaccines for Viruses and Cancer with Steve Reed HDT Bio

Apr 25, 2023 | In the News

Click here to view...

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned – PLOS Pathogens

Apr 19, 2023 | Publications

Click here to view...

Fierce Biotech: HDT Bio’s Zika and HIV vaccines generate immune responses in pregnant rabbits and their offspring

Mar 27, 2023 | In the News

Click here to view...

Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model – Molecular Therapy

Mar 24, 2023 | Publications

Click here to view...
« Older Entries
Next Entries »

Recent Posts

  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
  • Institutional Biosafety Committee
  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow